☆ 4.4 Editorial Material

If cancer stem cells are resistant to current therapies, what's next?

FUTURE ONCOLOGY (2009)

Journal

FUTURE ONCOLOGY

Volume 5, Issue 6, Pages 747-750

Publisher

FUTURE MEDICINE LTD

DOI: 10.2217/FON.09.58

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Pharmacology & Pharmacy

Cancer stem cells: Recent insights and therapies

Hongyu Zhou, Licheng Tan, Beilei Liu, Xin-Yuan Guan

Summary: Tumors consist of malignant components that generate abnormal tissues through self-renewal and differentiation. Cancer stem cells (CSCs) play a fundamental role in maintaining tumor heterogeneity and remodeling the tumor microenvironment. Recent advances in technology have allowed for better understanding of CSC characteristics, markers, mechanisms, and their interactions with other cells in the tumor microenvironment.

BIOCHEMICAL PHARMACOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Cisplatin-Resistant CD44+ Lung Cancer Cells Are Sensitive to Auger Electrons

Karina Lindbog Madsen, Oke Gerke, Poul F. Hoilund-Carlsen, Birgitte Brinkmann Olsen

Summary: Cancer stem cells (CSCs) are resistant to conventional therapy and responsible for cancer relapse. Auger electron emitters show promising potential in eradicating resistant lung cancer CD44(+) populations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Ivan Henriquez, Mack I. I. I. I. I. I. Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gomez, Oscar Abuchaibe, Felipe Counago

Summary: mCRPC is a complex disease with a wide range of molecular tumor behavior and high risk of progression, making early detection and treatment crucial. Treatment options have improved significantly in recent years, but clinicians find it challenging to keep up with the rapidly changing therapeutic landscape.

BIOMEDICINES (2021)

Add to Collection

Review Oncology

Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies

Isis Wolf, Christian Gratzke, Philipp Wolf

Summary: Despite research and improvements in diagnosis and therapy, prostate cancer (PC) remains a major challenge. Recent findings have highlighted the role of PC stem cells (PCSCs) in tumorigenesis, relapse, metastasis, and treatment resistance. This review discusses the impact of PCSCs in clinical practice and presents new therapeutic approaches to improve outcomes for PC patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Cell Biology

Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases

Alvaro Sierra-Sanchez, Trinidad Montero-Vilchez, Maria I. Quinones-Vico, Manuel Sanchez-Diaz, Salvador Arias-Santiago

Summary: The use of human mesenchymal stem cells for the treatment of skin diseases has emerged as a promising strategy, with various sources and clinical studies being actively explored. However, further research is needed to determine the best treatment approach for each patient and disease.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies

Vahideh Keyvani, Espanta Riahi, Meysam Yousefi, Seyed-Alireza Esmaeili, Rana Shafabakhsh, Amin Moradi Hasan-Abad, Maryam Mahjoubin-Tehran, Michael R. Hamblin, Samaneh Mollazadeh, Hamed Mirzaei

Summary: This article discusses the molecular mechanism of gynecologic cancer and the role of cancer stem cells (CSCs) in treatment, aiming to discover more specific therapeutic approaches to gynecologic cancer.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Immunology

Next Generation Natural Killer Cells for Cancer Immunotherapy

Fiorella Rossi, Nathaniel Fredericks, Andrew Snowden, Michael J. Allegrezza, Uriel Y. Moreno-Nieves

Summary: Immunotherapy for cancer, particularly CAR-T cell therapies, has become the standard of care for certain malignancies, but their complexity and cost limit their application. As an alternative, engineered NK cells are gaining interest due to their potent anti-tumor activity and potential for safer and more accessible production. This article reviews the advancements in engineering NK cells for cancer immunotherapy, including sourcing, engineering technologies, clinical trials, receptor engineering, and stealth approaches. The future of NK cell products with enhanced functionality and tumor-infiltration potential is also discussed.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Cancer stem cells targets and combined therapies to prevent cancer recurrence

Pawan Kumar Raghav, Zoya Mann

Summary: Cancer stem cells play a crucial role in tumorigenesis and present challenges for treatment. Despite multiple treatment options available, the lack of specificity and dose limitation hinders complete efficacy in controlling CSCs.

LIFE SCIENCES (2021)

Add to Collection

Review Engineering, Biomedical

Immunoengineering the next generation of arthritis therapies

Molly Klimak, Robert J. Nims, Lara Pferdehirt, Kelsey H. Collins, Natalia S. Harasymowicz, Sara J. Oswald, Lori A. Setton, Farshid Guilak

Summary: Immunoengineering has advanced new approaches for treating joint diseases such as osteoarthritis and rheumatoid arthritis, emphasizing the importance of precise targeting and controlled delivery strategies for better therapeutic outcomes. By leveraging biomaterials and genetic engineering, immunoengineering has the potential to revolutionize the understanding, treatment, and prevention of joint diseases.

ACTA BIOMATERIALIA (2021)

Add to Collection

Review Medicine, Research & Experimental

Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria

Yuan Liu, Ziwen Tong, Jingru Shi, Ruichao Li, Mathew Upton, Zhiqiang Wang

Summary: Antimicrobial resistance poses a global health challenge, but a combination of antibiotics and non-antibiotic compounds offers an effective strategy. A pathogen-by-pathogen approach highlights the critical value of drug repurposing.

THERANOSTICS (2021)

Add to Collection

Article Multidisciplinary Sciences

Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies

Shamin Li, Yannick Simoni, Summer Zhuang, Austin Gabel, Shaokang Ma, Jonathan Chee, Laura Islas, Anthony Cessna, Jenette Creaney, Robert K. Bradley, Alec Redwood, Bruce W. Robinson, Evan W. Newell

Summary: This study characterizes neoantigen-specific CD8+ T cells in a tumor that is resistant to immune checkpoint blockade treatment and neoantigen vaccination. Despite an expansion of neoantigen-specific CD8+ tumor-infiltrating lymphocytes, tumor regression was not observed, suggesting important implications for future immunotherapeutic strategies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Pharmacology & Pharmacy

Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications

Xiaobin Zeng, Chengxiao Liu, Jie Yao, Haoqiang Wan, Guoqing Wan, Yingpeng Li, Nianhong Chen

Summary: Both hereditary and sporadic breast cancer may stem from a subcomponent of stem cells with dysregulated self-renewal pathways. Cancer stem cells play a crucial role in treatment resistance and tumor initiation, highlighting the importance of therapeutic strategies targeting these cells.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Osteogenesis Imperfecta: Current and Prospective Therapies

Malwina Botor, Agnieszka Fus-Kujawa, Marta Uroczynska, Karolina L. Stepien, Anna Galicka, Katarzyna Gawron, Aleksander L. Sieron

Summary: Osteogenesis Imperfecta is a group of connective tissue disorders characterized by bone fragility, with five types ranging from mild to lethal. Current treatments aim to prevent fractures, control symptoms, and increase bone mass, but have limitations in effectiveness and side effects. Experimental approaches, including stem cell transplantation and genetic engineering, show promise in improving therapeutic effects.

BIOMOLECULES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies

Jacek R. Wilczynski, Milosz Wilczynski, Edyta Paradowska

Summary: This review provides an overview of the biology of ovarian cancer stem cells (OCSCs) and their impact on chemo-resistance and prognosis in ovarian cancer patients. It discusses the role of OCSCs in cancer progression and recurrence, as well as potential treatment options targeted specifically at OCSCs.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Oncology

Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies

Dunne Fong, Chase T. Christensen, Marion M. Chan

Summary: Cancer is a complex multistep process involving genetic and environmental factors leading to genetic and epigenetic changes. Cancer stem cells play a crucial role in tumor progression and are a subpopulation of tumor cells with self-renewal and differentiation abilities. Repurposing FDA-approved drugs to target resistant cancer cells, such as CSCs, can improve cancer treatment efficacy.

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells

Dejan Vidovic, Thomas T. Huynh, Prathyusha Konda, Cheryl Dean, Brianne M. Cruickshank, Mohammad Sultan, Krysta M. Coyle, Shashi Gujar, Paola Marcato

CELL DEATH AND DIFFERENTIATION (2020)

Add to Collection

Article Oncology

Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance

Margaret L. Dahn, Brianne M. Cruickshank, Ainsleigh J. Jackson, Cheryl Dean, Ryan W. Holloway, Steven R. Hall, Krysta M. Coyle, Hillary Maillet, David M. Waisman, Kerry B. Goralski, Carman A. Giacomantonio, Ian C. G. Weaver, Paola Marcato

MOLECULAR CANCER THERAPEUTICS (2020)

Add to Collection

Review Cell Biology

The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

Justin M. Brown, Marie-Claire D. Wasson, Paola Marcato

CELLS (2020)

Add to Collection

Article Medicine, Research & Experimental

Human-specific GAPDH qRT-PCR is an accurate and sensitive method of xenograft metastasis quantification

Margaret L. Dahn, Cheryl A. Dean, Diana B. Jo, Krysta M. Coyle, Paola Marcato

Summary: The introduction of human-specific GAPDH qRT-PCR method allows quantification of metastasis in murine xenograft models without the requirement of overexpressed exogenous genes. This method is more sensitive and correlates well with histological analysis, making it a possible primary method for quantifying disseminated human cells in xenograft models.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2021)

Add to Collection

Review Oncology

Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection

Justin M. Brown, Marie-Claire D. Wasson, Paola Marcato

Summary: The COVID-19 pandemic has posed challenges to cancer management, particularly for triple-negative breast cancer (TNBC) patients, with delays in treatment potentially affecting their survival. TNBC treatment guidelines are evolving, with further research needed to fully understand the impact of COVID-19 on TNBC patients. Furthermore, TNBC patients with metastatic disease may face additional vulnerability to SARS-CoV-2 infection, highlighting the importance of prioritizing their care during the pandemic.

CANCERS (2021)

Add to Collection

Article Oncology

S100A10 Has a Critical Regulatory Function in Mammary Tumor Growth and Metastasis: Insights Using MMTV-PyMT Oncomice and Clinical Patient Sample Analysis

Alamelu G. Bharadwaj, Margaret L. Dahn, Rong-Zong Liu, Patricia Colp, Lynn N. Thomas, Ryan W. Holloway, Paola A. Marignani, Catherine K. L. Too, Penelope J. Barnes, Rosaline Godbout, Paola Marcato, David M. Waisman

CANCERS (2020)

Add to Collection

Editorial Material Oncology

Targeting the Roots of Recurrence: New Strategies for Eliminating Therapy-Resistant Breast Cancer Stem Cells

Margaret L. Dahn, Paola Marcato

CANCERS (2021)

Add to Collection

Article Oncology

An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer

Mohammad Sultan, Jacob T. Nearing, Justin M. Brown, Thomas T. Huynh, Brianne M. Cruickshank, Emily Lamoureaux, Dejan Vidovic, Margaret L. Dahn, Wasundara Fernando, Krysta M. Coyle, Carman A. Giacomantonio, Morgan G. Langille, Paola Marcato

Summary: The study identified BCL6 as a potential targetable resistance biomarker of paclitaxel response in breast cancer, with knockdown of BCL6 resulting in increased tumor regression and enhanced paclitaxel treatment efficacy. This suggests that targeting BCL6 may be a promising strategy to improve the response to paclitaxel in breast cancer patients.

MOLECULAR ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR

Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Marika Forsythe, Daniel French, John Fris, Wenda Greer, Harry Henteleff, Mary MacNeil, Paola Marignani, Wojciech Morzycki, Madelaine Plourde, Stephanie Snow, Paola Marcato, Zhaolin Xu

Summary: Most lung cancer patients are diagnosed at an advanced stage with limited treatment options. Research has found correlations between driver gene mutations and PD-L1 expression in lung cancer cases, providing insights into optimal patient management.

PLOS ONE (2021)

Add to Collection

Article Oncology

LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack

Jaganathan Venkatesh, Marie-Claire D. Wasson, Justin M. Brown, Wasundara Fernando, Paola Marcato

Summary: Studies have shown that long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) play crucial regulatory roles in the pathogenesis of breast cancer, forming complex regulatory networks of post-transcriptional gene regulation. Depending on specific lncRNA/miRNA interactions, the lncRNA-miRNA axis can have either tumor suppressor or oncogenic effects, making it important for determining therapeutic targets.

CANCER LETTERS (2021)

Add to Collection

Article Oncology

LncRNA PART1 Promotes Proliferation and Migration, Is Associated with Cancer Stem Cells, and Alters the miRNA Landscape in Triple-Negative Breast Cancer

Brianne M. Cruickshank, Marie-Claire D. Wasson, Justin M. Brown, Wasundara Fernando, Jaganathan Venkatesh, Olivia L. Walker, Fiorella Morales-Quintanilla, Margaret L. Dahn, Dejan Vidovic, Cheryl A. Dean, Carter VanIderstine, Graham Dellaire, Paola Marcato

Summary: This study demonstrates that lncRNA PART1 is enriched in triple-negative breast cancers and cancer stem cells, and is associated with worse outcomes in some breast cancer patients. PART1 alters the miRNA landscape, leading to genome-wide mRNA expression regulation, making it an attractive target for the treatment of triple-negative breast cancers.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention

Raj Pranap Arun, Hannah F. Cahill, Paola Marcato

Summary: The regulatory and functional roles of non-coding RNAs, especially microRNAs, in cancer are critical. Understanding the altered miRNA landscape in breast cancer is important for revealing breast cancer signaling and identifying potential therapeutic targets.

BIOMEDICINES (2022)

Add to Collection

Review Oncology

The Expanding Role of Cancer Stem Cell Marker ALDH1A3 in Cancer and Beyond

Meghan E. McLean, Maya R. MacLean, Hannah F. Cahill, Raj Pranap Arun, Olivia L. Walker, Marie-Claire D. Wasson, Wasundara Fernando, Jaganathan Venkatesh, Paola Marcato

Summary: This article provides a review of the role of ALDH1A3 in normal physiology, cancer, and other diseases, as well as the potential of targeting ALDH1A3 with non-specific and specific inhibitors.

CANCERS (2023)

Add to Collection

Article Cell Biology

Three-dimensional growth sensitizes breast cancer cells to treatment with ferroptosis-promoting drugs

Sandhya Chipurupalli, Peijia Jiang, Xiaoyang Liu, Julia Linhares Santos, Paola Marcato, Kirill V. Rosen

Summary: Drugs that induce iron-mediated cell death, known as ferroptosis, show promise for cancer treatment. In the study of breast cancer, the ferroptosis-inducing drug erastin was found to significantly inhibit tumor growth in mice, but only minimally reduce growth in 2D cell culture. However, when tested on 3D breast cancer cell cultures, erastin and sulfasalazine showed stronger inhibition. The mechanism behind this differential effect involves the upregulation of autophagy stimulators and heme oxygenase-1 (HO-1) in 2D culture cells compared to 3D culture cells.

CELL DEATH & DISEASE (2023)

Add to Collection

Article Multidisciplinary Sciences

TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway

Shekoufeh Almasi, Andra M. Sterea, Wasundara Fernando, Derek R. Clements, Paola Marcato, David W. Hoskin, Shashi Gujar, Yassine El Hiani

SCIENTIFIC REPORTS (2019)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.